Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?

During the 19th International Myeloma Society Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Roman Hájek, University of Ostrava, Ostrava, CZ. We asked, Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?

Hájek begins by explaining that isatuximab is an anti-CD38 monoclonal antibody currently approved for treatment in combination with pomalidomide + dexamethasone or carfilzomib + dexamethasone. This is followed by a discussion on why these combinations may be helpful for patients previously exposed or refractory to lenalidomide.

Hosted on Acast. See acast.com/privacy for more information.